The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and regulatory T (Treg) cells.
IL-2 is often expressed in various cancers, including melanoma, renal cell carcinoma, and certain hematological malignancies. Its expression can vary depending on the tumor type and the immune context.
Tumor-infiltrating lymphocytes (TILs), particularly activated T cells, are significant sources of IL-2 in the tumor microenvironment.
IL-2 is primarily known for its role in promoting anti-tumor immunity. It stimulates the proliferation and activation of T cells, enhancing their ability to recognize and kill tumor cells.
(Will delete Record if Target field = "Delete") Home